Telehealth has made GLP-1 medications far more accessible than they were, which is a genuine advance for people who would otherwise wait months. It has also produced a wide quality range, from programs that function like a clinic to ones that function like a vending machine — and the difference is not visible from a polished website. Here is how the process works and how to tell them apart.
Where we stand: Menova is an independent publication. We sell no medication and prescribe nothing. We do earn referral commissions from some care providers we compare, disclosed on our affiliate disclosure page, and it never changes what we say. This is general education, not medical advice.
The process, step by step
- Intake questionnaire — weight history, medical history, medications, eating patterns.
- Labs, requested or reviewed when clinically appropriate — typically HbA1c, and often lipids, kidney, liver, and thyroid function.
- Clinical review or visit — a video consultation, or an asynchronous review by a clinician who messages you.
- Eligibility decision. A responsible program can say no, and sometimes should.
- Prescription, sent to a retail pharmacy or a partner mail pharmacy.
- Titration — starting low and increasing over months, with check-ins as the dose rises.
- Ongoing monitoring, including side effects, weight, and — if the program is good — muscle and nutrition.
What a proper intake asks about
If these do not come up, the evaluation is thin:
- Weight history and what you have tried before
- Personal or family history of medullary thyroid carcinoma or MEN2 — a contraindication
- History of pancreatitis, gallbladder disease, or significant gastrointestinal conditions such as gastroparesis
- Eating disorder history, current or past — this matters and is frequently skipped
- Diabetes status, kidney and liver function
- All current medications, including oral contraceptives and thyroid medication, whose absorption can be affected
- Pregnancy status or plans — these medications are not used in pregnancy, and note that improved fertility with weight loss is a real consideration
Green flags
- A named, licensed clinician reviews your intake — not only an algorithm
- Labs requested or reviewed where clinically appropriate
- FDA-approved medication from a licensed pharmacy, with the source stated plainly
- Side effect monitoring built into the program rather than optional
- A clear titration plan and defined criteria for pausing or stopping
- You can reach a clinician between visits without paying each time
- Transparent pricing, including what happens if you stop
- They talk about protein and resistance training unprompted
That last one is a genuine quality signal. Rapid weight loss takes muscle with it, and in midlife that worsens the metabolic problem you are trying to solve — see GLP-1s for perimenopause weight gain.
Red flags
- A prescription within minutes of signing up, with no meaningful clinical exchange
- Pressure to buy long subscription bundles before you have started
- Compounded medication offered without explaining what compounding means, or presented as equivalent to the approved product
- No discussion of side effects, contraindications, or stopping criteria
- Marketing that promises a specific number of pounds
- No named clinician and no way to reach one
- Cancellation terms buried in the footer
- Nothing about muscle, protein, or exercise anywhere in the program
The compounded question, stated plainly
Compounded semaglutide and tirzepatide were widely sold during manufacturer shortages, often at lower prices, and the regulatory picture has shifted as those shortages resolved.
Where this stands, with dates. The FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage in February 2025, and the grace period that had allowed widespread compounding ended in May 2025. In April 2026 the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the list of bulk substances outsourcing facilities may compound from, having found no clinical need — a proposal, not yet a final rule, with comments taken through June 2026. Narrow exceptions remain for a documented clinical need for an individual patient.
That matters when you are looking at a price. A compounded GLP-1 advertised at a fraction of the approved product is operating in a lane the regulator has been closing, which is a different proposition from a discount.
Compounded drugs are not FDA-approved products: they are not reviewed for safety, effectiveness, or manufacturing quality in the same way, and dosing errors have been reported with vials requiring self-measurement.
That does not make every compounded product dangerous, but it does mean you should know which you are being sold and why. Ask directly: is this FDA-approved medication, or compounded — and if compounded, from which pharmacy? A program that is evasive about this has answered the question. We apply the same standard to hormones in compounded versus FDA-approved HRT.
What it costs
Three separate costs, often blurred together in marketing:
- The program or membership fee — the consultation and ongoing access
- The medication — which varies enormously depending on brand, dose, and whether insurance covers it
- Labs, if not included
Insurance coverage for weight management indications is inconsistent and frequently excluded, while coverage for type 2 diabetes is more common. Costs also rise as your dose escalates, so ask what month twelve looks like, not month one. Manufacturer savings programs exist for some approved products and are worth asking about.
Questions to ask before you pay
- Is this FDA-approved medication or compounded, and from where?
- What is the total cost over twelve months, including dose escalation and labs?
- Who is the prescribing clinician, and what happens if I have a problem at week six?
- What side effects mean we pause or stop?
- How will we protect and monitor muscle mass?
- What is the plan if I stop the medication?
- What are the cancellation terms?
Before you start, rule out the other causes
Midlife fatigue and weight change are not always metabolic. Thyroid disease, iron deficiency, and sleep apnea produce the same picture and are all treatable — see when menopause might not be the answer, low ferritin in perimenopause, and sleep apnea after menopause. And if broken sleep from night sweats is driving the appetite changes, treating that may do more than a prescription — see midlife weight and energy changes.
Comparing programs
The services differ most on medication source, clinician access, monitoring, and total cost. Our GLP-1 program comparison lays those out side by side, and semaglutide versus tirzepatide covers the medication choice itself.
The free 2-minute Menova self-check helps you separate what is menopausal from what is metabolic before you commit — no account, not a diagnosis, and your answers never leave your device.
If you have seen berberine sold as a "natural Ozempic", it is not one — see the newer supplements. Also: semaglutide versus tirzepatide, GLP-1s in perimenopause, and losing weight in midlife.
This article is general education, not medical advice, and not an endorsement of any provider. GLP-1 medications are prescription drugs with boxed warnings and significant contraindications. Verify pricing and medication source directly, and decide with a licensed clinician who knows your history.
Sources: FDA — Semaglutide Medications, FDA — Human Drug Compounding, NIDDK — Weight Management, and ACOG.